{"id":"palifermin-before-only","safety":{"commonSideEffects":[{"rate":null,"effect":"Dysgeusia (taste alteration)"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Hyperplasia of oral tissues"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Palifermin binds to fibroblast growth factor receptor 2 (FGFR2) on epithelial cells, triggering signaling pathways that increase cell proliferation, differentiation, and migration. This accelerates the regeneration and repair of oral and gastrointestinal mucosa damaged by chemotherapy or radiation, reducing the severity and duration of mucositis.","oneSentence":"Palifermin is a recombinant human fibroblast growth factor 7 (FGF-7) that stimulates epithelial cell proliferation and differentiation to promote healing of damaged mucous membranes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:55.020Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Oral mucositis in patients receiving myeloablative chemotherapy and hematopoietic stem cell transplantation"},{"name":"Mucositis prevention in cancer patients undergoing high-dose chemotherapy or chemoradiation"}]},"trialDetails":[{"nctId":"NCT06959771","phase":"PHASE1, PHASE2","title":"Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-16","conditions":"CD40L-HyperIgM Syndrome","enrollment":1},{"nctId":"NCT06325709","phase":"PHASE1, PHASE2","title":"Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-04-17","conditions":"Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease","enrollment":10},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06851767","phase":"PHASE1, PHASE2","title":"Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-05-09","conditions":"X-linked Severe Combined Immunodeficiency, X-SCID, XSCID","enrollment":18},{"nctId":"NCT00629798","phase":"PHASE2","title":"Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-02-12","conditions":"Acute Myeloid Leukemia, Advanced Myelodysplastic Syndromes","enrollment":64},{"nctId":"NCT00626639","phase":"PHASE1, PHASE2","title":"A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2005-07","conditions":"Mucositis, Head and Neck Cancer","enrollment":5},{"nctId":"NCT00094861","phase":"PHASE2","title":"Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2005-01","conditions":"Dysphagia, Non-Small Cell Lung Cancer, Lung Cancer","enrollment":100},{"nctId":"NCT00131638","phase":"PHASE3","title":"A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-01","conditions":"Head and Neck Cancer","enrollment":241},{"nctId":"NCT00101582","phase":"PHASE3","title":"Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2005-08","conditions":"Mucositis, Solid Tumors, Stomatitis","enrollment":188},{"nctId":"NCT00434161","phase":"PHASE3","title":"A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2006-12","conditions":"Multiple Myeloma","enrollment":281},{"nctId":"NCT00352703","phase":"PHASE4","title":"PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2006-04","conditions":"Non-Hodgkin's Lymphoma, Multiple Myeloma","enrollment":145},{"nctId":"NCT00109031","phase":"PHASE3","title":"Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2005-01","conditions":"Cancer, Lymphoma, Leukemia","enrollment":47},{"nctId":"NCT00267046","phase":"PHASE2","title":"Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-12","conditions":"Sarcoma, Oral Mucositis","enrollment":49},{"nctId":"NCT00540332","phase":"PHASE1, PHASE2","title":"A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy","status":"WITHDRAWN","sponsor":"Swedish Orphan Biovitrum","startDate":"2007-10","conditions":"Head and Neck Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Kepivance"],"phase":"phase_3","status":"active","brandName":"Palifermin before only","genericName":"Palifermin before only","companyName":"Swedish Orphan Biovitrum","companyId":"swedish-orphan-biovitrum","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Palifermin is a recombinant human fibroblast growth factor 7 (FGF-7) that stimulates epithelial cell proliferation and differentiation to promote healing of damaged mucous membranes. Used for Oral mucositis in patients receiving myeloablative chemotherapy and hematopoietic stem cell transplantation, Mucositis prevention in cancer patients undergoing high-dose chemotherapy or chemoradiation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}